Key result
Atorvastatin reduces induced AF duration by ~67% in sterile pericarditis.
Why the study?
The effect of statin therapy on atrial fibrillation associated with tissue inflammation was unclear.
Does atorvastatin reduce atrial fibrillation duration and inflammation in a canine sterile pericarditis model?
RCT (n=20)
randomly assigned
Does atorvastatin reduce atrial fibrillation duration and inflammation in a canine sterile pericarditis model?
Atorvastatin reduces inflammation and prevents the maintenance of atrial fibrillation in a canine sterile pericarditis model, suggesting a potential therapeutic role for statins in AF.
Answers are grounded in this paper and cite their sources.
Atorvastatin attenuated postoperative AF in this model but should not change practice; leaves open anti-inflammatory benefits in human AF.
OBJECTIVE: It has been recently reported that AF is associated with tissue inflammation. Statins reduce C-reactive protein (CRP) levels. However, the effect of statin on atrial fibrillation (AF) is unclear. The purpose of the present study was to evaluate the effect of statin on AF in a canine sterile pericarditis model. METHODS: Sterile pericarditis was created in 20 dogs randomly assigned to two groups: a control group (10 dogs) and an atorvastatin treatment group (10 dogs). Atorvastatin was administered orally (2 mg/kg/day) beginning 1 week before the operation until the end of the study. Before and 2 days after the operation, CRP levels, the duration of induced AF, the atrial effective refractory period (AERP), and intra-atrial conduction time were determined. RESULTS: Before the operation, there were no significant differences in any of the parameters between the two groups. On the second postoperative day, the atorvastatin group had a lower CRP level (7.6+/-0.5 versus 11.7+/-1.3 mg/dl, P<0.0001), a shorter AF duration (177+/-57 versus 534+/-189 s, P<0.0001), a longer AERP (138+/-6 versus 130+/-6 ms, P<0.01), and a shorter intra-atrial conduction time (46+/-3 versus 51+/-5 ms, P<0.01) than the control group. CONCLUSIONS: Atorvastatin can prevent maintenance of AF by inhibiting inflammation in the canine sterile pericarditis model. Atorvastatin may thus be a novel therapeutic agent for AF.
No takes yet. Share an insight, caveat, or question.
Koichiro Kumagai (2004) conducted an RCT in Atrial fibrillation (n=20). Atorvastatin vs. Control was evaluated on Duration of induced AF (s) (p=<0.0001). Atorvastatin reduced the duration of induced atrial fibrillation compared to control in a canine sterile pericarditis model.
Synapse has enriched 10 related papers. Consider them for comparative context: